References
Original article
Mease, P. J. et al. Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. Rheumatology (Oxford) https://doi.org/10.1093/rheumatology/keac353 (2022)
Coates, L. C. et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study. Arthritis Rheumatol. https://doi.org/10.1002/art.42280 (2022)
Baraliakos, X. et al. Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study. Arthritis Rheumatol. https://doi.org/10.1002/art.42282 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Phillips, R. Bimekizumab safe and effective for AS and PsA in long-term trials. Nat Rev Rheumatol 18, 494 (2022). https://doi.org/10.1038/s41584-022-00823-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-022-00823-2
- Springer Nature Limited